Last reviewed · How we verify
NeisVac-C®
NeisVac-C is a meningococcal serogroup C conjugate vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup C.
NeisVac-C is a meningococcal C conjugate vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup C. Used for Prevention of meningococcal disease caused by Neisseria meningitidis serogroup C in infants, children, adolescents, and adults.
At a glance
| Generic name | NeisVac-C® |
|---|---|
| Also known as | Meningococcal group C polysaccharide conjugate vaccine adsorbed, Meningococcal C conjugate vaccine (Baxter)., MenC-TT |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Meningococcal conjugate vaccine |
| Target | Neisseria meningitidis serogroup C polysaccharide capsule |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains polysaccharide capsular antigen from N. meningitidis serogroup C conjugated to a protein carrier, which enhances immunogenicity and promotes T-cell dependent immune responses. This results in the production of protective antibodies that prevent invasive meningococcal disease caused by serogroup C strains.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C in infants, children, adolescents, and adults
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Irritability
- Drowsiness
- Loss of appetite
Key clinical trials
- Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers (PHASE3)
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines (PHASE3)
- Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose (PHASE2)
- Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) (PHASE3)
- Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010) (PHASE3)
- A Study of the Interaction Between BCG And MenC Immunisation: BAM (PHASE4)
- RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016) (PHASE3)
- Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NeisVac-C® CI brief — competitive landscape report
- NeisVac-C® updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI